Jazz Pharmaceuticals plc
JAZZ · NASDAQJazz Pharmaceuticals reported 2025 revenue of $4.27 billion and Q1 2026 revenue of $1.07 billion. The thesis turns on whether specialty medicines, pipeline investment and portfolio execution can convert strong cash generation into durable earnings after a loss-making annual operating baseline.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.